Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of LY2495655 in older patients with recent falls and muscle weakness
2011-006062-40Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in muscle atrophy comparing LY2495655 with Placebo (2 arms). Primary endpoint: Change from baseline in appendicular lean body mass. Started May 2012; status: completed.
02
Drugs
landogrozumab
03
Conditions
muscle atrophy
Beyond the preview
Go deeper on 2011-006062-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006062-40.